VVOS · Vivos Therapeutics, Inc.
$0.31
-0.03 (-9.29%)
At close · Aug 17
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Without additional financing, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.91M
Shares
20.12M
Vivos Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Vivos Therapeutics, Inc. (VVOS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲38.1%
$4.55M
−$5.45M
'21 Q3
21-11-15
▲32.9%
$4.39M
−$7.39M
'21 Q4
22-03-31
▲5.7%
$3.64M
−$5.33M
'22 Q1
22-05-16
▼6.6%
$4.25M
−$5.43M
'22 Q3
22-11-22
▼10.1%
$3.95M
−$6.09M
'22 Q4
23-03-30
▲5.8%
$3.86M
−$1.70M
'23 Q1
23-06-08
▼18.9%
$3.40M
−$5.53M
'23 Q2
23-08-16
▼17.8%
$3.25M
−$4.26M
'23 Q4
24-03-29
▼11.4%
$3.42M
−$3.76M
'24 Q1
24-05-15
▲19.4%
$4.05M
−$1.93M
'24 Q2
24-08-15
▲16.9%
$3.86M
−$2.62M
'24 Q3
24-11-14
▲13.9%
$3.70M
−$2.83M
'24 Q4
25-03-31
▼11.8%
$3.02M
−$3.86M
'25 Q1
25-05-15
▼5.8%
$3.82M
−$5.01M
'25 Q2
25-08-20
▲75.7%
$6.78M
−$5.40M
'25 Q3
25-11-19
LATEST
▲70.5%
$5.14M
−$7.68M
'26 Q1
26-04-15
Earnings call
FY26 · Q1
2026-04-15
Vivos Therapeutics, Inc. Q1 FY2026 Earnings Call
Positive tone
SCN Acquisition Revenue Growth
Cardiologist Collaborations and OSA Market
Gross Margin Expansion
Revenue
$5.14M
▲ 70.5% YoY Diluted EPS
$-0.52
Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-11-19
Vivos Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
Sleep Center of Nevada (SCN) acquisition integration
Provider staffing and ramp-up
New medical specialty affiliations (cardiology, neurology)
Revenue
$6.78M
▲ 75.7% YoY Diluted EPS
$-0.49
Gross margin
58.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-20
Vivos Therapeutics, Inc. Q2 FY2025 Earnings Call
Positive tone
Sleep Center of Nevada acquisition and integration
Revenue decline and financial pressure
SO Teams deployment and operations
Revenue
$3.82M
▼ 5.8% YoY Diluted EPS
$-0.55
Gross margin
55.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Vivos Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
SCN Acquisition
Business Model Pivot to Sleep Centers
Financing and Capital Structure
Revenue
$3.02M
▼ 11.8% YoY Diluted EPS
$-0.45
Gross margin
50.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Vivos Therapeutics, Inc. Q4 FY2024 Earnings Call
Revenue
$3.70M*
▲ 13.9% YoY Gross margin
56.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Vivos Therapeutics, Inc. Q3 FY2024 Earnings Call
Positive tone
CPT codes and reimbursement
VIP enrollment decline and deemphasis
DME and DSO channel underperformance
Revenue
$3.86M
▲ 16.9% YoY Diluted EPS
$-0.40
Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
Vivos Therapeutics, Inc. Q2 FY2024 Earnings Call
Positive tone
VIP enrollment program
Operating expenses outlook
FDA regulatory clearance
Revenue
$4.05M
▲ 19.4% YoY Diluted EPS
$-0.60
Gross margin
65.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Vivos Therapeutics, Inc. Q1 FY2024 Earnings Call
Positive tone
VIP enrollment program
Strategic revenue initiative / new partnerships
Revenue decline and headwinds
Revenue
$3.42M
▼ 11.4% YoY Diluted EPS
$-1.63
Gross margin
56.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Vivos Therapeutics, Inc. Q4 FY2023 Earnings Call
Positive tone
Cost Reduction and Operating Expenses
FDA Regulatory Clearances
Cash Flow Breakeven and Profitability Path
Revenue
$3.25M*
▼ 17.8% YoY Gross margin
64.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q2
2023-08-16
Vivos Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$3.40M
▼ 18.9% YoY Diluted EPS
$-4.62
Gross margin
61.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-06-08
Vivos Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$3.86M
▲ 5.8% YoY Diluted EPS
$-1.72
Gross margin
60.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Vivos Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$3.95M*
▼ 10.1% YoY Gross margin
60.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-22
Vivos Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$4.25M
▼ 6.6% YoY Diluted EPS
$-6.40
Gross margin
58.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Vivos Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$3.64M
▲ 5.7% YoY Diluted EPS
$-6.25
Gross margin
70.0%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Vivos Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$4.39M*
▲ 32.9% YoY Gross margin
70.7%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Vivos Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$4.55M
▲ 38.1% YoY Gross margin
70.0%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Vivos Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$4.50M
▲ 37.5% YoY Gross margin
80.6%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Vivos Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$3.45M
▲ 7.9% YoY Gross margin
78.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Vivos Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$3.31M*
Gross margin
81.3%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Showing 1–19 of 19 earnings calls
Key facts
CIK
1716166
CUSIP
92859E207
13F (30d)
21 filings
21 filers
Visit website
Investor relations